^
Association details:
| Biomarker: | NUP214-ABL1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) + Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy
Published date:
02/04/2022
Excerpt:
Here, we report a case with a NUP214-ABL1 fusion detected at relapse by multiplexed, targeted RNA sequencing....we started CD19-directed therapy with blinatumomab, highly effective in eradicating MRD,22 and switched dasatinib to ponatinib...Indeed, 4 weeks after this therapeutic change, MRD was absent by flow cytometry and NGS...this data demonstrates for the first time that the combination of blinatumomab with ponatinib has the potential to effectively treat dasatinib-resistance manifesting as MRD recurrence in NUP214-ABL1+B-ALL.
DOI:
10.1093/oncolo/oyab052
